The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury

被引:30
作者
Arevalo-Martin, Angel [1 ]
Garcia-Ovejero, Daniel [1 ]
Molina-Holgado, Eduardo [1 ]
机构
[1] Hosp Nacl Paraplej SESCAM, Unidad Neurol Expt, Lab Neuroinflamac, Toledo 45071, Spain
关键词
Cannabinoid; CB1; CB2; 2-AG; Oligodendrocyte; Myelin; SCI; CB1 CANNABINOID RECEPTORS; DIFFUSION-WEIGHTED MRI; MULTIPLE-SCLEROSIS; MURINE MODEL; IN-VIVO; SYSTEM; BRAIN; NEUROPROTECTION; ACTIVATION; 2-AG;
D O I
10.1016/j.nbd.2010.02.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A series of pathological events secondary to spinal cord injury (SCI) contribute to the spread of the damage, which aggravates neurological deficits. Here we report that a single dose of the neuroprotective endocannabinoid 2-arachidonoyl glycerol (2-AG) administered early after SCI reduces lesion expansion, which was prevented by simultaneous blockade of both CB1 and CB2 receptors but not by blockade of either receptor alone. Treatment with 2-AG also preserves the white matter around the epicenter of the injury. Moreover, in the preserved white matter, 2-AG protects myelin from damage and reduces oligodendrocyte loss. In addition to these protective actions at the epicenter region, 2-AG also inhibits the myelin damage and delayed oligodendrocyte loss induced at 10 mm from the epicenter. Interestingly, the early protective action of 2-AG is maintained 28 days after injury, when the lesion size is still smaller and the preservation of white matter is better in 2-AG-treated animals. Therefore, our results show that 2-AG protects from the expansion of the lesion and white matter damage, which suggest that this endogenous cannabinoid may be useful as a protective treatment for acute SCI. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:304 / 312
页数:9
相关论文
共 36 条
  • [1] Arévalo-Martin A, 2003, J NEUROSCI, V23, P2511
  • [2] Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2
    Arevalo-Martin, Angel
    Garcia-Ovejero, Daniel
    Rubio-Araiz, Ana
    Gomez, Oscar
    Molina-Holgado, Francisco
    Molina-Holgado, Eduardo
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2007, 26 (06) : 1548 - 1559
  • [3] Prominent role of the spinal central pattern generator in the recovery of locomotion after partial spinal cord injuries
    Barriere, Gregory
    Leblond, Hugues
    Provencher, Janyne
    Rossignol, Serge
    [J]. JOURNAL OF NEUROSCIENCE, 2008, 28 (15) : 3976 - 3987
  • [4] Imaging in chronic spinal cord injury - indications and benefits
    Bodley, R
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2002, 42 (02) : 135 - 153
  • [5] Endocannabinoids: synthesis and degradation
    Di Marzo, V.
    [J]. REVIEWS OF PHYSIOLOGY, BIOCHEMISTRY AND PHARMACOLOGY, VOL 160, 2008, 160 : 1 - 24
  • [6] Protection in Animal Models of Brain and Spinal Cord Injury with Mild to Moderate Hypothermia
    Dietrich, W. Dalton
    Atkins, Coleen M.
    Bramlett, Helen M.
    [J]. JOURNAL OF NEUROTRAUMA, 2009, 26 (03) : 301 - 312
  • [7] QUANTITATIVE MRI OF SPINAL-CORD INJURY IN A RAT MODEL
    FALCONER, JC
    NARAYANA, PA
    BHATTACHARJEE, MB
    LIU, SJ
    [J]. MAGNETIC RESONANCE IN MEDICINE, 1994, 32 (04) : 484 - 491
  • [8] The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats
    Fernandez-Lopez, David
    Pazos, M. Ruth
    Tolon, Rosa M.
    Moro, M. Angeles
    Romero, Julian
    Lizasoain, Ignacio
    Martinez-Orgado, Jose
    [J]. PEDIATRIC RESEARCH, 2007, 62 (03) : 255 - 260
  • [9] MRI CHARACTERIZATION OF DIFFUSION-COEFFICIENTS IN A RAT SPINAL-CORD INJURY MODEL
    FORD, JC
    HACKNEY, DB
    ALSOP, DC
    JARA, H
    JOSEPH, PM
    HAND, CM
    BLACK, P
    [J]. MAGNETIC RESONANCE IN MEDICINE, 1994, 31 (05) : 488 - 494
  • [10] Mechanisms of control of neuron survival by the endocannabinoid system
    Galve-Roperh, Ismael
    Aguado, Tania
    Palazuelos, Javier
    Guzman, Manuel
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (23) : 2279 - 2288